Novartis Ag (Adr) (NVS) Shareholder Schafer Cullen Capital Management INC Has Lowered Position by $17.49 Million as Share Value Declined

Novartis AG (NYSE:NVS) Logo

Schafer Cullen Capital Management Inc decreased its stake in Novartis Ag (Adr) (NVS) by 7.91% based on its latest 2018Q4 regulatory filing with the SEC. Schafer Cullen Capital Management Inc sold 205,782 shares as the company’s stock declined 0.59% while stock markets rallied. The hedge fund held 2.40M shares of the major pharmaceuticals company at the end of 2018Q4, valued at $205.52 million, down from 2.60 million at the end of the previous reported quarter. Schafer Cullen Capital Management Inc who had been investing in Novartis Ag (Adr) for a number of months, seems to be less bullish one the $213.77B market cap company. The stock increased 1.38% or $1.27 during the last trading session, reaching $93.29. About 2.66M shares traded or 27.70% up from the average. Novartis AG (NYSE:NVS) has risen 8.33% since March 17, 2018 and is uptrending. It has outperformed by 3.96% the S&P500.

Schafer Cullen Capital Management Inc, which manages about $10.62B and $6.49B US Long portfolio, upped its stake in Vodafone Group Plc (Adr) (NASDAQ:VOD) by 411,110 shares to 1.55M shares, valued at $29.85 million in 2018Q4, according to the filing.

Analysts await Novartis AG (NYSE:NVS) to report earnings on April, 18. They expect $1.24 EPS, down 3.13 % or $0.04 from last year’s $1.28 per share. NVS’s profit will be $2.84B for 18.81 P/E if the $1.24 EPS becomes a reality. After $1.24 actual EPS reported by Novartis AG for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

More notable recent Novartis AG (NYSE:NVS) news were published by: which released: “FDA OKs new generic version of Novartis’ Diovan – Seeking Alpha” on March 12, 2019, also with their article: “Daily Biotech Pulse: KaryoPharm’s Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA – Benzinga” published on March 15, 2019, published: “Sandoz chief departs, spin-off looming? – Seeking Alpha” on March 14, 2019. More interesting news about Novartis AG (NYSE:NVS) were released by: and their article: “Here’s Why Ligand Pharmaceuticals Is Having a Bad Day – Motley Fool” published on March 06, 2019 as well as‘s news article titled: “Amarin up 12% on (another) M&A rumor – Seeking Alpha” with publication date: February 22, 2019.

Novartis AG (NYSE:NVS) Ratings Coverage

Among 3 analysts covering Novartis (NYSE:NVS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Novartis had 3 analyst reports since November 19, 2018 according to SRatingsIntel. The stock of Novartis AG (NYSE:NVS) has “Buy” rating given on Tuesday, December 11 by Jefferies. The rating was upgraded by Goldman Sachs to “Conviction Buy” on Monday, November 19. The rating was upgraded by Cowen & Co to “Outperform” on Monday, November 26.

Novartis AG (NYSE:NVS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.